New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
13:05 EDTTSPT, SNYFDA doesn't require labeling changes for Intermezzo in review of sleep aids
The FDA announced earlier that it is requiring Sanofi (SNY), the manufacturer of Ambien, and some makers of other insomnia drugs that contain zolpidem, to lower the recommended dose. The FDA said the recommended bedtime dose should be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. The FDA said recommended doses of Transcept Pharmaceuticals' (TSPT) Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzo’s approval in November 2011, the label already recommended a lower dosage for women than for men, the FDA noted. In afternoon trading, shares of Transcept rose 16c, or 3.04%, to $5.43. Reference Link
News For TSPT;SNY From The Last 14 Days
Check below for free stories on TSPT;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
July 21, 2014
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 16, 2014
09:03 EDTSNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use